第一颗智能药丸:数字革命还是最后的喘息?

IF 1.1 4区 哲学 Q3 ETHICS
Anna K. Swartz, Phoebe Friesen
{"title":"第一颗智能药丸:数字革命还是最后的喘息?","authors":"Anna K. Swartz, Phoebe Friesen","doi":"10.1353/ken.2023.a917930","DOIUrl":null,"url":null,"abstract":"<p><p>Abilify MyCite was granted regulatory approval in 2017, becoming the world’s first “smart pill” that could digitally track whether patients had taken their medication. The new technology was introduced as one that had gained the support of patients and ethicists alike, and could contribute to solving the widespread and costly problem of patient nonadherence. Here, we offer an in-depth exploration of this narrative, through an examination of the origins and development of Abilify, the drug that would later become MyCite. This history illuminates how an antipsychotic can become a top-selling drug and maintain its blockbuster status for more than a decade. It also provides a detailed case study for how knowledge is constructed within the logic of biomedical capitalism, providing impetus to reexamine claims regarding how MyCite addresses patient nonadherence, engenders patient support, and is ethicist-approved.</p></p>","PeriodicalId":46167,"journal":{"name":"Kennedy Institute of Ethics Journal","volume":"1 1","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The First Smart Pill: Digital Revolution or Last Gasp?\",\"authors\":\"Anna K. Swartz, Phoebe Friesen\",\"doi\":\"10.1353/ken.2023.a917930\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Abilify MyCite was granted regulatory approval in 2017, becoming the world’s first “smart pill” that could digitally track whether patients had taken their medication. The new technology was introduced as one that had gained the support of patients and ethicists alike, and could contribute to solving the widespread and costly problem of patient nonadherence. Here, we offer an in-depth exploration of this narrative, through an examination of the origins and development of Abilify, the drug that would later become MyCite. This history illuminates how an antipsychotic can become a top-selling drug and maintain its blockbuster status for more than a decade. It also provides a detailed case study for how knowledge is constructed within the logic of biomedical capitalism, providing impetus to reexamine claims regarding how MyCite addresses patient nonadherence, engenders patient support, and is ethicist-approved.</p></p>\",\"PeriodicalId\":46167,\"journal\":{\"name\":\"Kennedy Institute of Ethics Journal\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kennedy Institute of Ethics Journal\",\"FirstCategoryId\":\"98\",\"ListUrlMain\":\"https://doi.org/10.1353/ken.2023.a917930\",\"RegionNum\":4,\"RegionCategory\":\"哲学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ETHICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kennedy Institute of Ethics Journal","FirstCategoryId":"98","ListUrlMain":"https://doi.org/10.1353/ken.2023.a917930","RegionNum":4,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ETHICS","Score":null,"Total":0}
引用次数: 0

摘要

2017 年,Abilify MyCite 获得监管部门批准,成为世界上首款可数字化追踪患者是否服药的 "智能药片"。这项新技术的推出得到了患者和伦理学家的支持,有助于解决患者普遍存在的不依从性问题,而且成本高昂。在此,我们将通过对后来成为 MyCite 的药物 Abilify 的起源和发展的研究,对这一叙述进行深入探讨。这段历史揭示了一种抗精神病药物是如何成为畅销药物,并将其畅销地位维持了十多年的。它还提供了一个详细的案例研究,说明知识是如何在生物医学资本主义的逻辑中构建起来的,从而推动我们重新审视有关 MyCite 如何解决患者不依从性、吸引患者支持以及获得伦理学家批准的说法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The First Smart Pill: Digital Revolution or Last Gasp?

Abilify MyCite was granted regulatory approval in 2017, becoming the world’s first “smart pill” that could digitally track whether patients had taken their medication. The new technology was introduced as one that had gained the support of patients and ethicists alike, and could contribute to solving the widespread and costly problem of patient nonadherence. Here, we offer an in-depth exploration of this narrative, through an examination of the origins and development of Abilify, the drug that would later become MyCite. This history illuminates how an antipsychotic can become a top-selling drug and maintain its blockbuster status for more than a decade. It also provides a detailed case study for how knowledge is constructed within the logic of biomedical capitalism, providing impetus to reexamine claims regarding how MyCite addresses patient nonadherence, engenders patient support, and is ethicist-approved.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.00
自引率
0.00%
发文量
19
期刊介绍: The Kennedy Institute of Ethics Journal offers a scholarly forum for diverse views on major issues in bioethics, such as analysis and critique of principlism, feminist perspectives in bioethics, the work of the Advisory Committee on Human Radiation Experiments, active euthanasia, genetics, health care reform, and organ transplantation. Each issue includes "Scope Notes," an overview and extensive annotated bibliography on a specific topic in bioethics, and "Bioethics Inside the Beltway," a report written by a Washington insider updating bioethics activities on the federal level.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信